Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cormet is a sustained-release tablet formulation of metoprolol succinate, a cardioselective beta-1 adrenergic receptor antagonist. It is primarily used for the management of hypertension, angina pectoris, and cardiac arrhythmias, as well as for secondary prevention following a myocardial infarction. By competitively blocking beta-1 receptors in the heart, it reduces heart rate, cardiac output, and blood pressure. The sustained-release formulation allows for controlled delivery of the active ingredient, typically manufactured by Lia Life Sciences. It is designed to provide therapeutic effects over an extended period, often administered multiple times daily depending on the specific clinical requirement.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cormet.